Clinical Report: Safety and Efficacy of CD38-Targeted CAR-T Therapy in RRMM

Overview

This systematic review and meta-analysis evaluated CD38-directed CAR-T cell therapy in relapsed/refractory multiple myeloma (RRMM). Dual-target CD38/BCMA CAR-T demonstrated high overall response rates and manageable safety, whereas single-target CD38 CAR-T showed lower efficacy and higher mortality.

Background

Multiple myeloma is a hematologic malignancy with poor prognosis in relapsed/refractory cases despite advances in therapy. CAR-T cell therapy targeting antigens such as BCMA has shown promise, but antigen escape limits durability. CD38 is highly expressed on malignant plasma cells, making it a potential target for CAR-T therapy. Dual-target CD38/BCMA CAR-T constructs have emerged to improve efficacy and overcome resistance.

Data Highlights

Key Findings

• Dual-target CD38/BCMA CAR-T therapy achieved a pooled overall response rate of 89% in RRMM patients.
• Complete response or stringent complete response rates reached 63%, with 67% achieving MRD negativity.
• Mortality was substantially lower in dual-target therapy (11%) compared to single-target CD38 CAR-T (44%).
• High incidence of any-grade cytokine release syndrome (83%) was observed, with 26% experiencing grade ≥3 CRS.
• Other notable adverse events included infections (23%), ICANS (13%), and kidney injury (13%).
• Single-target CD38 CAR-T showed limited efficacy and higher mortality, indicating the need for cautious interpretation.

Clinical Implications

Dual-target CD38/BCMA CAR-T therapy offers a promising treatment option for RRMM with high response rates and manageable safety profiles. Clinicians should monitor for cytokine release syndrome and neurotoxicity, which remain significant adverse events. The limited data on single-target CD38 CAR-T suggest it is less effective and potentially more toxic, underscoring the importance of selecting optimal CAR-T constructs.

Conclusion

Dual-target CD38/BCMA CAR-T therapy demonstrates encouraging efficacy and acceptable safety in relapsed/refractory multiple myeloma. Further large-scale studies are needed to confirm these findings and define the optimal role of CD38-directed CAR-T therapies in clinical practice.

References

1. Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis